Glaukos Corporation Common Stock (GKOS)

The company's recent past featured robust growth, and it anticipates continued rises into the near future.

Glaukos (GKOS) Q3 2025 Earnings Call Transcript

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance.

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.

Glaukos (GKOS) smashed Q3 2025 earnings forecasts, sending its stock soaring. The company posted record revenue and raised its 2025 and 2026 sales guidance.

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.